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ABSTRACT
Objectives To investigate the temporal trends of 30-day
mortality and hospitalisation in US Veterans with COVID-19
and 30-day mortality in hospitalised veterans with
COVID-19 and to decompose the contribution of changes
in the underlying characteristics of affected populations to
these temporal changes.
Design Observational cohort study.
Setting US Department of Veterans Affairs.
Participants 49 238 US veterans with a positive
COVID-19 test between 20 March 2020 and 19 September
2020; and 9428 US veterans hospitalised with a positive
COVID-19 test during the same period.
Outcome measures 30-day mortality rate and
hospitalisation rate.
Results Between 20 March 2020 and 19 September 2020
and in COVID-19 positive individuals, 30-day mortality rate
dropped by 9.2% from 13.6% to 4.4%; hospitalisation rate
dropped by 16.8% from 33.8% to 17.0%. In hospitalised
COVID-19 individuals, 30-day mortality rate dropped
by 12.7% from 23.5% to 10.8%. Among COVID-19
positive individuals, decomposition analyses suggested
that changes in demographic, health and contextual
characteristics, COVID-19 testing capacity, and hospital
occupancy rates accounted for 40.2% and 33.3% of
the decline in 30-day mortality and hospitalisation,
respectively. Changes in the underlying characteristics of
hospitalised COVID-19 individuals accounted for 29.9% of
the decline in 30-day mortality.
Conclusion Between March and September 2020,
changes in demographic and health characteristics of
people infected with COVID-19 contributed measurably
to the substantial decline in 30-day mortality and
hospitalisation.

INTRODUCTION
Reports from regional health systems and the
Centre of Disease Control suggest substantial
temporal variations in COVID-19 mortality
rates1–3; however, a national temporal analysis of mortality and hospitalisation rates
accounting for individual-level characteristics
is lacking, and the relative contribution of
changes in demographic and health characteristics of people infected with COVID-19 to

Strengths and limitations of this study
►► National large-scale individual-level data from the

US Department of Veterans Affairs which operates
the largest integrated healthcare system in the USA.
►► Advanced decomposition methods disentangle the
influence of changes in demographics and health
characteristics on temporal trends of 30-day mortality and hospitalisation rates.
►► The study accounted for important but less studied
drivers of change in mortality and hospitalisation
including contextual variables, testing capacity and
hospital occupancy rates.
►► The veteran population includes mostly older white
men, which may limit the generalisability.

temporal differences in mortality rates is not
clear.
A deeper understanding of the changes in
hospitalisation and mortality rates and the
drivers of such changes in the first wave of the
pandemic will aid effort to optimise management of future waves of this global pandemic.
In this work, we leveraged the breadth and
depth of the US Department of Veterans
Affairs (VA) electronic healthcare databases
to describe temporal changes in mortality
rates and hospitalisation among COVID19-
positive veterans, and temporal changes
in mortality rates of hospitalised veterans
with COVID-19. We then decomposed the
contribution of changes in demographic,
health and contextual characteristics to these
temporal changes.
METHODS
Identification of COVID-19 test-positive
individuals
Using the comprehensive COVID-19 Shared
Data Resource (CSDR)4 5 developed by the
Department of VA, we identified unique US
veterans with their first laboratory-confirmed
COVID-19-
positive test between 20 March
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Data sources
Data were obtained from the VA CSDR4 and Corporate
Data Warehouse (CDW),6–18 which provides electronic
health record information during routine healthcare.
Demographic information and dates of death were
collected from the CDW SPatient domain. Patient clinical diagnoses, procedures and hospitalisation characteristics were obtained from the CDW outpatient encounter
and inpatient encounter domains. Smoking status was
obtained from the CDW health factors domain. Laboratory results, including serum creatinine, were obtained
from the CDW patient laboratory chemistry domain. Data
on height, weight and blood pressure were procured from
the CDW vital signs domain. The CDW outpatient pharmacy domain was used to obtain diabetes medication data.
The Planning System Support Group Enrollee provided
the Federal Information Processing Standard (FIPS)
code of residence. The 2015 Area Deprivation Index
(ADI) were obtained from the University of Wisconsin.
The ADI is a composite measure of a census block group’s
socioeconomic disadvantage and is constructed from data
elements including education, employment, housing
quality and poverty measures.19
Outcomes
We examined the temporal trends in (1) rates of 30-day
mortality and hospitalisation among those with a positive
COVID-19 test, and (2) rates of 30-day mortality among
those hospitalised with COVID-19. Thirty-day mortality
was defined as all-cause mortality occurring within the 30
days after the participant’s first COVID-19 positive test.
Hospitalisation is defined by a hospital admission between
5 days before and 30 days after the first COVID-19 positive
test.
Participant characteristics
Race was categorised as white, black and other. Health
features included body mass index (BMI) and smoking
status. BMI was computed from the last measurements of
the participant’s height and weight prior to and closest
to the first COVID-19-positive test date. Smoking status
was categorised as never smoker, former smoker and
current smoker, based on the most recent record prior to
the first COVID-19-positive test. Comorbidities included
2

Table 1 Characteristics of the individuals with COVID-19
and hospitalised individuals with COVID-19

Characteristic

Veterans with
COVID-19 (N=49 238)

Hospitalised
veterans with
COVID-19 (N=9428)

Demographics
 Age (years), median
(IQR)

63.3 (49.8–73.1)

70.6 (61.2–76.8)

 Race, n (%)
  
White

29 814 (60.6)

5054 (53.6)

  
Black

16 714 (33.9)

3809 (40.4)

  
Other

2710 (5.5)

565 (6.0)

 Sex (women), n (%)

5673 (11.5)

527 (5.6)

Health characteristics
 BMI category, n (%)
  
Underweight (<8.5
kg/m2)

265 (0.5)

83 (0.9)

  
Normal weight
(18.5–<25.0 kg/m2)

9939 (20.2)

1836 (19.5)

  
Overweight (25–
<30 kg/m2)

15 032 (30.5)

2922 (31.0)

  Obesity (>18.5 kg/
m2)

24 002 (48.7)

4587 (48.7)

  
Never smoker

27 492 (55.8)

4713 (50.0)

  
Former smoker

13 062 (26.5)

2956 (31.4)

  
Current smoker

8684 (17.6)

1759 (18.7)

 Hypertension, (%)

30 568 (62.1)

6347 (67.3)

 Diabetes, n (%)

13 717 (27.9)

3695 (39.2)

 Smoke, n (%)

 Cancer, n (%)

4558 (9.3)

1443 (15.3)

10 399 (21.1)

3417 (36.2)

 Cerebrovascular
disease, n (%)

5192 (10.5)

1836 (19.5)

 Dementia, n (%)

5350 (10.9)

1953 (20.7)

 Chronic kidney
disease, n (%)

9573 (21.9)

3042 (34.9)

 Peripheral artery
disease, n (%)

1411 (2.9)

543 (5.8)

504 (1.0)

141 (1.5)

 Cardiovascular
disease, n (%)

 HIV, n (%)
 Pneumonia, n (%)

765 (1.6)

336 (3.6)

7666 (15.6)

2429 (25.8)

  
0–33.3

10 248 (20.8)

1785 (18.9)

  
33.4–366.6

20 861 (42.4)

3643 (38.6)

  
66.7–100

18 129 (36.8)

4000 (42.4)

 COPD, n (%)
Contextual factors
 ADI rank category, n (%)

Testing capacity
 COVID-19 testing
capacity (per 10 000
people), mean (SD)

3.1 (1.9)

2.8 (1.8)

37.0 (10.8)

38.1 (10.5)

Hospital occupancy
 Hospital occupancy
(%), mean (SD)

ADI, Area Deprivation Index; COPD, chronic obstructive pulmonary disease.
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2020 and 19 September 2020. The CSDR captures
COVID-19 cases based on laboratory results that comply
with Centers for Disease Control and Prevention standards, including 2019-
nCOV reverse transcription-
PCR
Diagnostic Panel and the SARS-CoV-2 Multiplex Assay,
or human-confirmed case review.5 The VA had its first
COVID-19-positive patient on 2 March 2020. In this study,
20 March 2020 was selected as the first day of observation where it was the first day that VA had more than 100
COVID-19-positive patients nationally, facilitating stabilisation of rate calculations. We selected 19 September
2020 as the last day of observation to ensure 30 days of
follow-up for observation of outcomes.

Open access

Periods
20 March–19 April
20 April–19 May

COVID-19 patients
(total N)
5896
6685

30-day mortality,
n (%)

30-day mortality among
Hospitalisation, hospitalised
n (%)
COVID-19 patients, n (%)

13.6
12.3

33.8
17.2

23.5
17.0

20 May–19 June

4824

7.1

20.0

12.6

20 June–19 July

13 084

4.9

17.4

11.8

20 July–19 August

11 874

5.2

15.8

11.1

20 August–19 September
Overall

6875
49 238

4.4
7.2

17.0
19.1

10.8
14.8

cancer, cardiovascular disease, cerebrovascular disease,
chronic kidney disease, chronic obstructive pulmonary disease (COPD), dementia, diabetes mellitus, HIV,
hypertension, peripheral artery disease and pneumonia.
Cancer, cardiovascular disease, cerebrovascular disease,
dementia, HIV, peripheral artery disease, pneumonia and
COPD were identified in the 2 years prior to testing positive for COVID-19 through International Classification
of Diseases, 10th Version, Clinical Modification diagnosis
codes.18 20 Chronic kidney disease was defined as baseline
estimated glomerular filtration rate (eGFR) lower than
60 mL/min/1.73 m2. Baseline eGFR was calculated using
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation21 and was assessed as the veteran’s
last outpatient value prior to the date of first COVID-19
test positive. Participants who had no measurement of
baseline eGFR (n=5447, 11.1% for veterans with COVID19; n=717, 7.6% for hospitalised veterans with COVID19) were assumed to have no chronic kidney disease.
Diabetes was defined as any use of antihyperglycaemic
medications22 23 or incidence of haemoglobin A1C
greater or equal to 6.5%.24 Hypertension was defined as
median systolic blood pressure greater than or equal to
130 mm Hg or median diastolic blood pressure greater
than or equal to 80 mm Hg in 1 year.25 Participants who
had no measurement of blood pressure (n=2699, 5.5%
for veterans with COVID-19; n=235, 2.5% for hospitalised veterans with COVID-19) were assumed to have no
chronic kidney disease. ADI is a composite measure of a
geographical location’s socioeconomic disadvantage, and
ranges from 0 (low disadvantage) to 100 (high disadvantage). County-level ADI of the participants was assigned
based on the participant’s FIPS code of residence location at the first COVID-19 positive test date. Mean imputation was applied to missing values of covariates including
BMI (missing=111, 0.2% of veterans with COVID-19;
missing=11, 0.1% of hospitalised veterans with COVID-19)
and ADI (missing=1303, 2.6% of veterans with COVID-19;
missing=88, 1.0% of hospitalised veterans with COVID19). COVID-19 testing capacity was calculated as 7-day
averages of the number of COVID-19 tests conducted in
a hospital system divided by the total number of veterans
served in that hospital system in the last calendar year.
Cai M, et al. BMJ Open 2021;11:e047369. doi:10.1136/bmjopen-2020-047369

Hospital occupancy rate was defined as the percentage
of beds occupied by hospitalised patients in a hospital
system within a calendar week. COVID-19 testing capacity
and hospital occupancy rate were linked to the veterans
by the hospital system in which the individuals had their
first positive COVID-19 test.
Statistical analyses
We calculated and plotted 7-day moving averages of crude
and standardised 30-
day mortality and hospitalisation
rates in COVID-19-positive participants, as well as 30-day
mortality rates in hospitalised COVID-19-positive participants. The 7-day range included the current day, and the
3 days before and after. Standardised rates were adjusted
for age, race, gender, health behaviours (smoking status
and BMI), comorbidities and ADI through indirect standardisation.26 The standardisation was based on the ratio
difference between expected and observed number of
outcomes, where the expected number of outcomes was
estimated from individual-level logistic regressions.
To understand driving factors of the temporal tends
in the outcomes, we decomposed the contribution of
the changes in key participant characteristics to changes
in the observed rates of outcomes over time. We first
constructed individual-level logistic regression models for
the different outcomes using four sets of factor domains:
demographics (age, race and gender), health characteristics (BMI, diabetes, cancer, cardiovascular disease, cerebrovascular disease, chronic kidney disease, dementia,
HIV, hypertension, peripheral artery disease, pneumonia
and smoking status), contextual factors (ADI), COVID-19
testing capacity and hospital occupancy rate. Hospital
occupancy rate was not included as a predictor of hospitalisation since they are measuring the same variable. For
each individual, we then computed the expected probabilities of the outcome based on a participants observed
characteristics and under a reference characteristics set,
where probability of the outcome was minimised (age was
set as 0, and other categorical variables were set to be the
reference group). We estimated the additive contribution
of the six sets of factor domains to the estimated rates
of the outcome using decomposition analysis.27 Then the
change in outcome rates between the first (20 March–19
3
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Patient and public involvement
No patients were involved in developing the hypothesis,
the specific aims or the research questions, nor were they
involved in developing plans for design or implementation of the study. No patients were involved in the interpretation or writing up of results.

RESULTS
Between 20 March 2020 and 19 September 2020, we identified 49 238 US veterans who tested positive for COVID-19
and 9 428 US veterans hospitalised with COVID-19. Characteristics of the two cohorts are reported in table 1.
Among individuals with COVID-19, the median age was
63.3 years (IQR 49.8–73.1 years); 60.6% were white,
33.9% were black, and 11.5% were women. Among hospitalised individuals, the median age was 70.6 years (IQR
61.2–76.8 years); 53.6% were white, 40.4% were black,
and 6.0% were women.

Figure 1 Temporal trends of COVID-19 30-day mortality
and hospitalisation among US Veterans. (A,B) Thirty-day
mortality and hospitalisation rates in US Veterans who
had a positive COVID-19 test (n=29 528). (C) Thirty-day
mortality rate in hospitalised US veterans with a positive
COVID-19 test (n=6449). Fully standardised rates were
adjusted for, demographics (age, race and gender), health
characteristics (smoking status, Body Mass Index, cancer,
cardiovascular disease, chronic kidney disease, dementia,
type 2 diabetes mellitus, HIV, hypertension, peripheral artery
disease, pneumonia and stroke), contextual factors (ADI),
COVID-19 testing capacity and hospital occupancy. ADI, Area
Deprivation Index.

April) and the last (20 August–19 September) 30-
day
periods associated with each domain were calculated by
taking the difference of the contributions between the
two periods.
All statistical tests were two sided, and a p-value less
than 0.05 or a 95% CI that did not contain unity was
4

Temporal trends in 30-day mortality and hospitalisation rates
Between 20 March 2020 and 19 September 2020 and
among individuals with a COVID-19-
positive test, the
30-day mortality rate dropped by 9.2% from 13.6% to
4.4%; the hospitalisation rate dropped by 16.8% from
33.8% to 17.0% (table 2 and figure 1). Among hospitalised individuals with COVID-19, the 30-day mortality rate
dropped by 12.7% from 23.5% to 10.8% (table 2 and
figure 1). After accounting for demographics, contextual
factors, health characteristics, COVID-19 testing capacity
and hospital occupancy, standardised rates showed consistent decline during the period (figure 1).
Between 20 March 2020 and 19 September 2020 and
among hospitalised individuals with COVID-19, we
observed consistent decline in healthcare resource use
including decline in rates of intensive care unit (ICU)
admission, mechanical ventilator use and length of
hospital stay (online supplemental table 1). The rate of
ICU stay dropped by 4% from 35.6% to 31.6%; the rate of
mechanical ventilator use dropped by 11.3% from 20.6%
to 9.3%; the mean length of stay dropped by 4.2 days
from 13.8 to 9.6 days.
Predictors of 30-day mortality and hospitalisation
Adjusted ORs for the association between potential
day mortality and hospitalpredictors and risk of 30-
isation among veterans with COVID-19, as well as risk
day mortality among hospitalised veterans with
of 30-
COVID-19 are presented in table 3. Among veterans with
COVID-19, older age, black and other race, male gender,
current smoker, diabetes, cancer, cardiovascular disease,
dementia, chronic kidney disease, pneumonia, COPD
Cai M, et al. BMJ Open 2021;11:e047369. doi:10.1136/bmjopen-2020-047369
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considered statistically significant. Statistical analyses and
data visualisation were performed using SAS Enterprise
Guide V.7.1 and R V.4.0.2.28 The participants were not
involved in the design, conduct, reporting or dissemination plans of the study.
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Hospitalised veterans with
COVID-19

Veterans with COVID-19
Characteristics

30-day mortality

Hospitalisation

30-day mortality

Demographics
 Age

1.08 (1.07 to 1.08)

1.02 (1.02 to 1.02)

1.06 (1.06 to 1.07)

 Black

1.11 (1.01 to 1.22)

1.64 (1.56 to 1.74)

1.03 (0.90 to 1.18)

 Other

1.33 (1.12 to 1.58)

1.58 (1.42 to 1.76)

1.20 (0.92 to 1.57)

 Sex, women (reference=men)

0.52 (0.40 to 0.67)

0.74 (0.67 to 0.82)

0.72 (0.47 to 1.06)

 Underweight (<18.5 kg/m2)

1.03 (0.64 to 1.59)

1.26 (0.92 to 1.71)

0.67 (0.29 to 1.38)

2

 Overweight (25–<30 kg/m )

0.89 (0.80 to 1.00)

0.98 (0.91 to 1.06)

1.07 (0.90 to 1.29)

 Obesity (>18.5 kg/m2)

1.02 (0.92 to 1.15)

1.05 (0.98 to 1.13)

1.24 (1.03 to 1.49)

Race (reference=white)

Health characteristics
 BMI category (reference=normal wt)

Smoking status (reference=never smoker)
 Former smoker

1.15 (1.05 to 1.25)

1.01 (0.96 to 1.07)

1.11 (0.97 to 1.28)

 Current smoker

1.12 (0.99 to 1.27)

1.11 (1.03 to 1.19)

1.21 (1.00 to 1.46)

 Hypertension

0.87 (0.80 to 0.94)

1.10 (1.04 to 1.16)

0.81 (0.70 to 0.92)

 Diabetes

1.37 (1.26 to 1.49)

1.23 (1.16 to 1.29)

1.15 (1.00 to 1.31)

 Cancer

1.10 (0.99 to 1.22)

1.36 (1.27 to 1.47)

1.03 (0.88 to 1.21)

 Cardiovascular disease

1.17 (1.07 to 1.27)

1.43 (1.35 to 1.52)

1.15 (1.00 to 1.31)

 Cerebrovascular disease

1.09 (0.98 to 1.20)

1.38 (1.29 to 1.48)

1.04 (0.90 to 1.21)

 Dementia

1.81 (1.65 to 2.00)

1.52 (1.41 to 1.63)

1.37 (1.18 to 1.59)

 Chronic kidney disease

1.48 (1.36 to 1.61)

1.27 (1.20 to 1.35)

1.47 (1.28 to 1.68)

 Peripheral arterial disease

1.09 (0.92 to 1.29)

1.31 (1.16 to 1.48)

1.17 (0.92 to 1.47)

 HIV

1.05 (0.67 to 1.58)

1.50 (1.22 to 1.85)

1.23 (0.71 to 2.03)

 Pneumonia

1.44 (1.15 to 1.80)

2.00 (1.71 to 2.35)

1.22 (0.90 to 1.62)

 COPD

1.21 (1.10 to 1.32)

1.40 (1.31 to 1.49)

0.96 (0.83 to 1.11)

 33.3–66.6

0.99 (0.89 to 1.10)

1.03 (0.96 to 1.10)

0.94 (0.79 to 1.11)

 66.7–100.0

1.04 (0.93 to 1.16)

1.16 (1.09 to 1.25)

0.92 (0.77 to 1.09)

 COVID-19 testing capacity (per 10 0.92 (0.90 to 0.94)
000 veterans)

0.95 (0.94 to 0.96)

0.90 (0.86 to 0.93)

1.05 (1.01 to 1.08)

Not included

1.08 (1.02 to 1.15)

0.834

0.718

0.746

Contextual factors
 ADI rank (reference=1–33.2)

COVID-19 testing capacity

Hospital occupancy
 Hospital occupancy rate (an
increase of 10%)
 C-statistics

ADI, Area Deprivation Index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate.

and higher hospital occupancy rate were associated with
higher risk of 30-day mortality and hospitalisation; higher
COVID-19 testing capacity was associated with lower risk
of 30-day mortality and hospitalisation. Among hospitalised veterans with COVID-19, older age, male gender,
obesity, current smoker, diabetes, cardiovascular disease,
Cai M, et al. BMJ Open 2021;11:e047369. doi:10.1136/bmjopen-2020-047369

chronic kidney disease, dementia and higher hospital
occupancy rate were associated with higher risk of 30-day
mortality; higher COVID-19 testing capacity was associated with lower risk of 30-day mortality. The models for
30-day mortality and hospitalisation among those who
tested positive, and the model for 30-day mortality among
5
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Table 3 ORs (95% CIs) of predictors associated with 30-day mortality and hospitalisation among veterans and hospitalised
veterans with COVID-19
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hospitalised achieved reasonably good predictive performance, with the c-
statistics of 0.834, 0.718 and 0.746,
respectively. The c-statistics for nested models, showing
the predictive performance improvement when adding
different variable sets, are included in online supplemental table 2.
Temporal change of predictors of 30-day mortality and
hospitalisation
The demographic, health and contextual characteristics as well as hospital occupancy and testing capacity in
each 1-month interval after 20 March 2020 and before
19 September 2020 are described in figures 2 and 3 and
6

online supplemental table 3A,B. We observed substantial decline in percent of black patients over time in
both individuals with COVID-19 (from 47.2% to 25.5%,
dropping by 21.7%) and hospitalised individuals with
COVID-19 (from 54.4% to 28.2%, dropping by 26.3%).
The prevalence of comorbidities was consistently
dropping between the two periods in individuals with
COVID-19; the overall trend of comorbidity prevalence
was still declining while less consistent in hospitalised
individuals with COVID-19. In both of two cohorts, the
percent of individuals living in disadvantaged neighbourhood (higher ADI) and COVID-19 testing capacity
Cai M, et al. BMJ Open 2021;11:e047369. doi:10.1136/bmjopen-2020-047369
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Figure 2 Change in predictors of 30-day mortality and hospitalisation among US veterans with COVID-19 between 20
March and 19 April 2020 and 20 August and 19 September 2020. The yellow dots represent the prevalence of predictors in 20
March–19 April 2020, while the green dots represent the prevalence of predictors in 20 August–19 September 2020. In the delta
column, blue text indicates that the change of predictor leads to decrease in mortality and hospitalisation rates, while red text
indicates the change of predictor leads to decrease in mortality and hospitalisation rates. ADI, Area Deprivation Index; COPD,
chronic obstructive pulmonary disease.

Open access

were increasing over time, while hospital occupancy was
decreasing.
Contribution of changes in predictors to temporal changes in
30-day mortality and hospitalisation rates
Decomposition analyses showed that from 20 March 2020
to 19 September 2020 and among COVID-19-
positive
individuals, changes in demographics, health characteristics, contextual characteristics, expansion of testing
capacity and decreasing hospital occupancy contributed
to 26.1%, 7.6%, 5.4%, −1.1% and 2.2% of the decline
in 30-day mortality rates respectively. Altogether, these
predictors accounted for 40.2% of the decline in 30-day
Cai M, et al. BMJ Open 2021;11:e047369. doi:10.1136/bmjopen-2020-047369

mortality in veterans with COVID-19 (figure 4 and online
supplemental table 4).
Changes in demographics, health characteristics and
contextual characteristics, and expansion of testing
capacity, and decreasing hospital occupancy contributed
to 19.6%, 9.0%, −0.6% and 5.4% of the decline in hospitalisation rates. Altogether, they accounted for 33.3%
of the decline in hospitalisation rates in veterans with
COVID-19 (figure 4 and online supplemental table 4).
Among those hospitalised with COVID-19, changes in
demographic, health characteristics, contextual characteristics, expansion of testing capacity and decreasing
7
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Figure 3 Change in predictors of 30-day mortality among hospitalised US veterans with COVID-19 between 20 March and
19 April 2020 and between 20 August and 19 September 2020. The yellow dots represent the prevalence of predictors in 20
March–19 April 2020, while the green dots represent the prevalence of predictors in 20 August–19 September 2020. In the Δ
column, the blue text indicates that the change of predictor leads to decrease in mortality rates, while the red text indicates the
change of predictor leads to decrease in mortality rates. ADI, Area Deprivation Index; COPD, chronic obstructive pulmonary
disease.
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hospital occupancy accounted for 23.6%, 2.4%, −0.8%,
1.6% and 3.1% of the decline in 30-day mortality rate,
respectively. All predictors collectively accounted for
29.9% of the decline in 30-day mortality (figure 4 and
online supplemental table 4).
DISCUSSION
This analysis of temporal trends of COVID-19 hospitalisation and mortality suggests substantial decline between
March 2020 and September 2020. We also observed
substantial shifts in the demographic and health characteristics of those who tested positive for COVID-19 and
in those who were hospitalised with a positive COVID-19
test including substantial decline in the percentage of
black people and comorbidity burden as well as increase
in testing capacity and reduction in hospital occupancy
rates. Around 40.2% of the decline in mortality rates and
33.3% of decline in hospitalisation rates were explained
by changes in the underlying characteristics of people
who tested positive for COVID-19. Around 29.9% of
the decline in mortality rates among hospitalised individuals was explained by changes in their underlying
characteristics.
Our analysis highlights the influence of individual-level
demographic and health characteristics on hospitalisation and mortality rates in COVID-19. The contribution of
changes in testing capacity to these outcomes (although
small) was measurable. The contribution of hospital occupancy rates to decline in mortality rates also highlights the
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importance of this variable as policy makers and health
systems continue to optimise the public health response
to this pandemic and may also be useful in preparing for
and mitigating the impact of future pandemics.
Slightly more than half of decline in rates was not
predicted by the explanatory variables in our models
and likely reflects the influence of factors that are not
accounted for in our approach including improvement in
medical care (to the extent that it may have influenced the
outcomes), a putative seasonality effect and the potential
influence of the broader public health policy measures
on these outcomes. In particular, it has been postulated
that severity of COVID-19 may be proportionate to the
viral inoculum which initiates the infection in the human
host, and it is plausible that public health policies (eg,
physical distancing, masking, etc) may have reduced the
viral inoculum in some infected individuals and might
have consequently resulted in less severe COVID-19 (and
reduced hospitalisation and mortality)—a hypothesis
referred to as the variolation of coronavirus.29
Our findings not only provide insight into the dynamic
changes of key indicators of the COVID-19 pandemic
(mortality and hospitalisation rates) but also estimate of
the influence of individual and contextual parameters on
these indicators. The synergistic influence of both individual and contextual factors cannot be overstated.30 31
The COVID-19 pandemic has brought to prominence the
complex interplay of several dynamic drivers including
individual-level demographic and health characteristics,
Cai M, et al. BMJ Open 2021;11:e047369. doi:10.1136/bmjopen-2020-047369
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Figure 4 Contribution of changes in demographics, health characteristics, testing capacity, hospital occupancy and contextual
factors, and epidemiological changes to changes in 30-day mortality and hospitalisation rates between 20 March and 19
April 2020 and between 20 August and 19 September 2020. The red dot represents the observed change in rate of outcomes
between the two periods, and the blue dot represents the change predicted based on demographics, health, contextual
characteristics, COVID-19 testing capacity and hospital occupancy. Hospital occupancy is not considered as predictor for the
hospitalisation outcome model. Epidemiological changes collectively represent the difference between predicted and observed
rates and reflect the summative contribution of factors that are not accounted for in prediction models.
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